NRBO NeuroBo Pharmaceuticals, Inc. Stock Quote

NRBO [NASD]

Index	-	P/E	-	EPS (ttm)	-0.61	Insider Own	33.77%	Shs Outstand	26.66M	Perf Week	-2.79%
Market Cap	15.13M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	10.34M	Perf Month	-28.63%
Income	-14.80M	PEG	-	EPS next Q	-	Inst Own	32.50%	Short Float	2.31%	Perf Quarter	-31.81%
Sales	-	P/S	-	EPS this Y	63.90%	Inst Trans	-3.57%	Short Ratio	1.23	Perf Half Y	-67.01%
Book/sh	0.45	P/B	1.13	EPS next Y	-	ROA	-121.00%	Target Price	16.00	Perf Year	-82.18%
Cash/sh	0.39	P/C	1.30	EPS next 5Y	-	ROE	-140.90%	52W Range	0.41 - 6.57	Perf YTD	-58.36%
Dividend	-	P/FCF	-	EPS past 5Y	60.00%	ROI	-	52W High	-92.27%	Beta	0.68
Dividend %	-	Quick Ratio	8.90	Sales past 5Y	-	Gross Margin	-	52W Low	22.88%	ATR	0.07
Employees	5	Current Ratio	8.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	36.80	Volatility	10.87% 14.98%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	29.90%	Profit Margin	-	Rel Volume	0.24	Prev Close	0.51
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Apr 01 BMO	Payout	-	Avg Volume	194.36K	Price	0.51
Recom	2.00	SMA20	-7.66%	SMA50	-31.62%	SMA200	-70.05%	Volume	46,368	Change	0.20%

Jun-15-20

Initiated

H.C. Wainwright

Buy

$20

May-06-22 08:00AM	NeuroBo Pharmaceuticals, Inc. Expands Management Team with the Appointment of Matthew Bardin, PharmD, BCPS as Senior Vice President Operations PR Newswire
Apr-01-22 08:00AM	NeuroBo Pharmaceuticals Reports Full Year 2021 Financial Results PR Newswire
Mar-15-22 08:00AM	NeuroBo Pharmaceuticals, Inc. Expands Scientific Advisory Board with Appointment of Danamarie Belpulsi, M.D. PR Newswire +6.54%
Jan-28-22 04:30PM	NeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of Directors PR Newswire
Nov-15-21 08:00AM	NeuroBo Pharmaceuticals Reports Third Quarter 2021 Financial Results PR Newswire
Nov-04-21 08:00AM	NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer PR Newswire
Oct-13-21 08:00AM	NeuroBo Pharmaceuticals Announces Positive Recommendation from Independent Data Safety Monitoring Committee of Phase 2/3 Clinical Trial of ANA001 in Hospitalized Patients with Moderate to Severe COVID-19 PR Newswire +6.52%
Oct-05-21 01:13PM	NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering PR Newswire -7.17%
Oct-01-21 08:00AM	NeuroBo Pharmaceuticals Announces $14 Million Registered Direct Offering PR Newswire -32.80%
Sep-03-21 11:27AM	Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like Simply Wall St. -7.52%
Aug-16-21 08:00AM	NeuroBo Pharmaceuticals Reports Second Quarter 2021 Financial Results PR Newswire
Jul-12-21 08:30AM	NeuroBo Pharmaceuticals' Shareholders Elect Hyung Heon Kim and Andrew I. Koven to NeuroBo's Board of Directors PR Newswire
May-17-21 05:02PM	NeuroBo Pharmaceuticals Reports First Quarter 2021 Financial Results PR Newswire +5.56%
Apr-15-21 04:52PM	NeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update PR Newswire
Mar-24-21 08:00AM	NeuroBo Pharmaceuticals Receives Approval for Amendment of Contingent Value Rights for Gemcabene PR Newswire
Mar-05-21 08:30AM	NeuroBo Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference PR Newswire
Jan-21-21 04:05PM	NeuroBo Pharmaceuticals Closes $10.0 Million Private Placement PR Newswire
Jan-19-21 08:00AM	NeuroBo Pharmaceuticals Announces $10.0 Million Private Placement PR Newswire -13.93%
Jan-06-21 08:30AM	NeuroBo Pharmaceuticals Acquires ANA Therapeutics for Late-Stage Oral Antiviral Development Program PR Newswire +19.93%
Dec-21-20 05:08AM	Is NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) Popular Amongst Insiders? Simply Wall St.
Nov-13-20 04:30PM	NeuroBo Pharmaceuticals Reports Third Quarter 2020 Financial Results PR Newswire
Sep-02-20 08:30AM	NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors PR Newswire
Aug-11-20 03:00PM	NeuroBo Pharmaceuticals Reports Second Quarter 2020 Financial Results PR Newswire -8.40%
Jun-16-20 04:05PM	NeuroBo Pharmaceuticals to Join Russell 3000® and Microcap® Indexes PR Newswire
May-26-20 08:30AM	NeuroBo Pharmaceuticals Announces Continuation of Partial Clinical Hold of Gemcabene PR Newswire -5.31%
May-20-20 04:29PM	NeuroBo Pharmaceuticals Reports First Quarter 2020 Financial Results PR Newswire
Apr-21-20 08:30AM	NeuroBo Pharmaceuticals Announces Issuance of U.S. Patent, Providing Broad Coverage of NB-02 for Neurodegenerative Disorders PR Newswire
Apr-16-20 04:22PM	NeuroBo Pharmaceuticals Announces Closing of $7.5 Million Registered Direct Offering PR Newswire -17.06%
Apr-14-20 09:15AM	NeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering PR Newswire -43.27%
Mar-31-20 11:04AM	NeuroBo Pharmaceuticals (NASDAQ:NRBO) Is In A Good Position To Deliver On Growth Plans Simply Wall St. +7.50%
Mar-30-20 04:30PM	NeuroBo Pharmaceuticals Reports Year End 2019 Financial Results and Provides Corporate Strategic Update PR Newswire -11.26%
Jan-13-20 09:00AM	NeuroBo Pharmaceuticals to Present at Biotech Showcase 2020 in San Francisco Business Wire -9.40%
Jan-10-20 05:00PM	NeuroBo Pharmaceuticals and Gemphire Therapeutics Complete Merger Business Wire

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for coronavirus, neurodegenerative, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which has completed Phase 2 clinical trial to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience